Literature DB >> 9777947

Effects of growth factors and basement membrane proteins on the phenotype of U-373 MG glioblastoma cells as determined by the expression of intermediate filament proteins.

S Sultana1, R Zhou, M S Sadagopan, O Skalli.   

Abstract

Various growth factors and basement membrane proteins have been implicated in the pathobiology of astrocytomas. The goal of this study was to determine the relative contribution of these two factors in modulating the phenotype of U-373 MG glioblastoma cells as determined by the expression of the intermediate filament proteins glial fibrillary acidic protein, vimentin, and nestin. For these determinations, cells plated in serum-free medium were treated either with growth factors binding to tyrosine kinase receptors including transforming growth factor-alpha, epidermal growth factor, platelet-derived growth factor-AA, basic fibroblast growth factor, and insulin-like growth factor-1 or with basement membrane proteins including collagen IV, laminin, and fibronectin. The changes in the expression levels of intermediate filament proteins in response to these treatments were analyzed by quantitation of immunoblots. The results demonstrate that collagen IV and growth factors binding to tyrosine kinase receptors decrease the glial fibrillary acidic protein content of U-373 MG cells. Growth factors binding to tyrosine kinase receptors also decrease the vimentin content of these cells but do not affect their nestin content. On the other hand, basement membrane proteins decrease the nestin content of U-373 MG cells but do not affect their vimentin content. The significance of these results with respect to the role played by different factors in modulating the phenotype of neoplastic astrocytes during tumor progression is discussed.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9777947      PMCID: PMC1853038          DOI: 10.1016/S0002-9440(10)65660-X

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  81 in total

1.  GFA and S 100 protein levels as an index for malignancy in human gliomas and neurinomas.

Authors:  C M Jacque; M Kujas; A Poreau; M Raoul; P Collier; J Racadot; N Baumann
Journal:  J Natl Cancer Inst       Date:  1979-03       Impact factor: 13.506

2.  Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications.

Authors:  H Towbin; T Staehelin; J Gordon
Journal:  Proc Natl Acad Sci U S A       Date:  1979-09       Impact factor: 11.205

3.  The growth of cells in serum-free hormone-supplemented media.

Authors:  J Bottenstein; I Hayashi; S Hutchings; H Masui; J Mather; D B McClure; S Ohasa; A Rizzino; G Sato; G Serrero; R Wolfe; R Wu
Journal:  Methods Enzymol       Date:  1979       Impact factor: 1.600

4.  Glial fibrillary acidic protein in giant cell tumors of brain and other gliomas. A possible relationship to malignancy, differentiation, and pleomorphism of glia.

Authors:  P E Duffy; Y Y Huang; M M Rapport; L Graf
Journal:  Acta Neuropathol       Date:  1980       Impact factor: 17.088

5.  Human wild-type p53 adopts a unique conformational and phosphorylation state in vivo during growth arrest of glioblastoma cells.

Authors:  S J Ullrich; W E Mercer; E Appella
Journal:  Oncogene       Date:  1992-08       Impact factor: 9.867

6.  Determination of glial fibrillary acidic protein (GFAP) in human brain tumors.

Authors:  C M Jacque; C Vinner; M Kujas; M Raoul; J Racadot; N A Baumann
Journal:  J Neurol Sci       Date:  1978-01       Impact factor: 3.181

7.  Immunohistochemical localization of glial fibrillary acidic protein in human glial neoplasms.

Authors:  M E Velasco; D Dahl; U Roessmann; P Gambetti
Journal:  Cancer       Date:  1980-02       Impact factor: 6.860

8.  Vimentin, the 57 000 molecular weight protein of fibroblast filaments, is the major cytoskeletal component in immature glia.

Authors:  D Dahl; D C Rueger; A Bignami; K Weber; M Osborn
Journal:  Eur J Cell Biol       Date:  1981-06       Impact factor: 4.492

9.  Glial fibrillary acidic protein in human gliomas.

Authors:  J D van der Meulen; H J Houthoff; E J Ebels
Journal:  Neuropathol Appl Neurobiol       Date:  1978 May-Jun       Impact factor: 8.090

10.  Immunocytochemical demonstration of vimentin in astrocytes and ependymal cells of developing and adult mouse nervous system.

Authors:  J Schnitzer; W W Franke; M Schachner
Journal:  J Cell Biol       Date:  1981-08       Impact factor: 10.539

View more
  6 in total

1.  On the use of ratio standard curves to accurately quantitate relative changes in protein levels by Western blot.

Authors:  Aaron Pitre; Yihang Pan; Steve Pruett; Omar Skalli
Journal:  Anal Biochem       Date:  2006-11-27       Impact factor: 3.365

2.  Platelet-derived growth factor receptor independent proliferation of human glioblastoma cells: selective tyrosine kinase inhibitors lack antiproliferative activity.

Authors:  Dietmar Gross; Günther Bernhardt; Armin Buschauer
Journal:  J Cancer Res Clin Oncol       Date:  2006-05-31       Impact factor: 4.553

3.  The hyaluronan receptor RHAMM/IHABP in astrocytoma cells: expression of a tumor-specific variant and association with microtubules.

Authors:  Rixin Zhou; Xiao Wu; Omar Skalli
Journal:  J Neurooncol       Date:  2002-08       Impact factor: 4.130

4.  RNA interference of LRRK2-microarray expression analysis of a Parkinson's disease key player.

Authors:  K Häbig; M Walter; S Poths; O Riess; M Bonin
Journal:  Neurogenetics       Date:  2007-12-21       Impact factor: 2.660

5.  Structural changes in intermediate filament networks alter the activity of insulin-degrading enzyme.

Authors:  Ying-Hao Chou; Wen-Liang Kuo; Marsha Rich Rosner; Wei-Jen Tang; Robert D Goldman
Journal:  FASEB J       Date:  2009-07-07       Impact factor: 5.191

6.  Nestin expression in the cell lines derived from glioblastoma multiforme.

Authors:  Renata Veselska; Petr Kuglik; Pavel Cejpek; Hana Svachova; Jakub Neradil; Tomas Loja; Jirina Relichova
Journal:  BMC Cancer       Date:  2006-02-02       Impact factor: 4.430

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.